Hostname: page-component-76fb5796d-5g6vh Total loading time: 0 Render date: 2024-04-27T01:20:02.546Z Has data issue: false hasContentIssue false

Tratamiento del trastorno por déficit de atención con hiperactividad (tipo residual) con moclobemida

Published online by Cambridge University Press:  12 May 2020

L. Chamorro
Affiliation:
Sección de Psiquiatría, Hospital General Universitario de Guadalajara, Donantes de sangre s/n, 19002Guadalajara, España
I. López
Affiliation:
Sección de Psiquiatría, Hospital General Universitario de Guadalajara, Donantes de sangre s/n, 19002Guadalajara, España

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Cartas al editor
Copyright
Copyright © European Psychiatric Association 1995

References

Bibliografía

Parquet, PJ, Servant, D, Servant, DBailly, Det al. Monoamine oxidase inhibitor in the treatment of attention déficit disorder of residual type. A propos of a case. Encephale 1988; Nov-Dec, 14/6: 439–41.Google Scholar
Wenker, PH, Garfinkel, BD. Attention Deficit Hyperactivity Disorder: Adult Manifestations. In: Kaplan, HI, Sadock, BJ, eds. Comprehensivo Textbook Of Psychiatry, vol 2, 5th ed. Baltimore: Williams and Wilkins, 1989; 1837–41.Google Scholar
Biederman, J, Newcorn, J, Spnah, S. Comorbidity of Attention Deficit Hyperactivity Disorder with conduct, depressive, anxiety and other disorders. Am J Psychiatry 1991; 148/5: 564–77.Google ScholarPubMed
Shakim, WO, Asarnow, RF, Hess, Eet al. A clinical and demographic profile of a sample of adults with attention déficit hyperactivity disorder, residual state. Compr Psychiatry 1990; 31/5: 416–25.CrossRefGoogle Scholar
Trott, GE, Friese, HJ, Menzel, Met alUse of Moclobemide in children with attention deficit hyperactivity disorder. Psychophannacologv 1992; 106: SI 34–6.Google ScholarPubMed